These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11287079)

  • 1. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease.
    Rodríguez Díaz M; Abdala P; Barroso-Chinea P; Obeso J; González-Hernández T
    Behav Brain Res; 2001 Jul; 122(1):79-92. PubMed ID: 11287079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.
    Rodríguez M; Barroso-Chinea P; Abdala P; Obeso J; González-Hernández T
    Exp Neurol; 2001 May; 169(1):163-81. PubMed ID: 11312569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-lesion administration of 7-NI attenuated motor and non-motor deficits in 6-OHDA induced bilaterally lesioned female rat model of Parkinson's disease.
    Kumari R; Kumar JB; Luthra PM
    Neurosci Lett; 2015 Mar; 589():191-5. PubMed ID: 25528406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partial loss of dopaminergic neurons in the substantia nigra, ventrotegmental area and the retrorubral area -- model of the early beginning of Parkinson's symptomatology?
    Heim C; Sova L; Kurz T; Kolasiewicz W; Schwegler H; Sontag KH
    J Neural Transm (Vienna); 2002 May; 109(5-6):691-709. PubMed ID: 12111461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease.
    Quiroga-Varela A; Aguilar E; Iglesias E; Obeso JA; Marin C
    Neuroscience; 2017 Oct; 361():144-156. PubMed ID: 28823819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrapallidal administration of 6-hydroxydopamine mimics in large part the electrophysiological and behavioral consequences of major dopamine depletion in the rat.
    Abedi PM; Delaville C; De Deurwaerdère P; Benjelloun W; Benazzouz A
    Neuroscience; 2013 Apr; 236():289-97. PubMed ID: 23376117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity.
    Dabbeni-Sala F; Di Santo S ; Franceschini D; Skaper SD; Giusti P
    FASEB J; 2001 Jan; 15(1):164-170. PubMed ID: 11149904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory pattern and phrenic and hypoglossal nerve activity during normoxia and hypoxia in 6-OHDA-induced bilateral model of Parkinson's disease.
    Andrzejewski K; Jampolska M; Zaremba M; Joniec-Maciejak I; Boguszewski PM; Kaczyńska K
    J Physiol Sci; 2020 Mar; 70(1):16. PubMed ID: 32160868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model.
    Fatemi I; Abdollahi A; Shamsizadeh A; Allahtavakoli M; Roohbakhsh A
    Acta Neuropsychiatr; 2021 Feb; 33(1):15-21. PubMed ID: 32967746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.
    Oiwa Y; Sanchez-Pernaute R; Harvey-White J; Bankiewicz KS
    J Neurosurg; 2003 Jan; 98(1):136-44. PubMed ID: 12546362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model.
    Warraich ST; Allbutt HN; Billing R; Radford J; Coster MJ; Kassiou M; Henderson JM
    Brain Res Bull; 2009 Feb; 78(2-3):85-90. PubMed ID: 18822357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histaminergic activity in a rodent model of Parkinson's disease.
    Nowak P; Noras L; Jochem J; Szkilnik R; Brus H; Körossy E; Drab J; Kostrzewa RM; Brus R
    Neurotox Res; 2009 Apr; 15(3):246-51. PubMed ID: 19384597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a new low-dose 6-hydroxydopamine model of Parkinson's disease in rat.
    Penttinen AM; Suleymanova I; Albert K; Anttila J; Voutilainen MH; Airavaara M
    J Neurosci Res; 2016 Apr; 94(4):318-28. PubMed ID: 26762168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.